Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Cisplatin + Etoposide + Panobinostat + Radiotherapy |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 6 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
Etoposide | Vepesid | EPEG|Eposin|VP-16|VP-16-213 | TOPO2 inhibitor 4 | Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary). |
Panobinostat | Farydak | LBH589 | HDAC Inhibitor 38 | Farydak (panobinostat) is an HDAC inhibitor, which induces cell-cycle arrest and decreases growth of tumor cells (PMID: 18349321, PMID: 19671764, PMID: 27802904). Farydak (panobinostat) is FDA approved, in combination with Velcade (Bortezomib) and dexamethasone, for multiple myeloma (FDA.gov). |
Radiotherapy |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | lung non-small cell carcinoma | not applicable | Cisplatin + Etoposide + Panobinostat + Radiotherapy | Phase I | Actionable | In a Phase I trial, Farydak (panobinostat) in combination with chemotherapy (cisplatin and etoposide) and radiotherapy resulted in durable partial response in all (3) treated patients with stage III non-small cell lung cancer (PMID: 26317683). | 26317683 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|